Join

Compare · CRL vs PPD

CRL vs PPD

Side-by-side comparison of Charles River Laboratories International Inc. (CRL) and PPD, Inc. (PPD): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CRL and PPD operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
  • PPD is the larger of the two at $16.64B, about 1.9x CRL ($8.73B).
  • CRL has hit the wire 17 times in the past 4 weeks while PPD has been quiet.
  • CRL has more recent analyst coverage (25 ratings vs 1 for PPD).
MetricCRLPPD
Company
Charles River Laboratories International Inc.
PPD, Inc.
Price
$181.33-2.43%
$47.29-0.07%
Market cap
$8.73B
$16.64B
1M return
-0.16%
-
1Y return
+22.97%
-
Industry
Biotechnology: Commercial Physical & Biological Resarch
Biotechnology: Commercial Physical & Biological Resarch
Exchange
NYSE
NASDAQ
IPO
2000
2020
News (4w)
17
0
Recent ratings
25
1
CRL

Charles River Laboratories International Inc.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.

PPD

PPD, Inc.

PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.

Latest CRL

Latest PPD